Hematin

• CAT Number: M079273
• CAS Number: 15489-90-4
• Molecular Formula: C34H33FeN4O5
• Molecular Weight: 633.49
• Purity: ≥95%
• Synonyms: 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid;iron(3+);hydroxide
• InChI: InChI=1S/C34H34N4O4.Fe.H2O/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);;1H2/q;+3;/p-3
• InChIKey: BMUDPLZKKRQECS-UHFFFAOYSA-K
• SMILES: CC1=C(C2=CC3=C(C(=C([N-]3)C=C4C(=C(C(=N4)C=C5C(=C(C(=N5)C=C1[N-]2)C)C=C)C)C=C)C)CCC(=O)O)CCC(=O)O.[OH-].[Fe+3]

Hematin (Cat No.: M079273) is a dark brown to black crystalline compound formed by the oxidation of heme, featuring an iron(III) ion coordinated within a porphyrin ring. It plays a critical role in biochemical research and clinical diagnostics, particularly as a heme analog and in studying hemoprotein functions. Hematin is also used therapeutically to reduce porphyrin synthesis in patients with acute porphyrias. Its iron center allows it to interact with oxygen and other ligands, making it valuable in enzymology, spectroscopy, and drug development studies.

Reference

[1]. Siegert SW, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008 Sep;25(9):842-57.
[Content Brief]

[2]. Green D, et al. The inactivation of hemostatic factors by hematin. J Lab Clin Med. 1983;102: 361-369.
[Content Brief]

[3]. Amin ML, et al. Development of hematin conjugated PLGA nanoparticle for selective cancer targeting. Eur J Pharm Sci. 2016 Aug 25;91:138-43.
[Content Brief]

[4]. Goetsch C, et al. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315: 235-238.
[Content Brief]

[5]. Quadros HC, et al. The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs. Pharmaceuticals (Basel). 2022;15(1):60. Published 2022 Jan 4.
[Content Brief]